AnaBios Corporation services

Functional Assays

CardioPRIME - Clinical Translation With Human Cardiac Tissue

CardioPRIME^® is the AnaBios approach for measuring human cardiomyocyte functionality and sets the industry standard for cardiac-based biomedical research. By leveraging the robust excitation-contraction coupling of mature primary human cardiomyocytes and direct measurements of sarcomeric length, CardioPRIME offers unprecedented insight into cardiomyocyte functionality and provides clinically translatable measurements and biomarkers for proarrhythmia, inotropy, Ca²⁺signaling, electrophysiology and cell health.

AnaBios - Heart Tissue Assays

EX VIVO Human Platforms for Cardiovascular Drug Discovery. Broadly defined, cardiovascular disease is the leading cause of death for men and women across most racial and ethnic groups in the United States with one person dying approximately every 34 seconds1. To drive successful clinical translation of new cardiovascular medicine, AnaBios develops relevant human ex vivo platforms for many cardiovascular diseases, including—but not limited to—heart failure with preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF), atrial fibrillation and arrhythmogenic disorders. These platforms are designed to identify relevant targets, verify therapeutic approaches and ultimately enable successful clinical translation for new compounds and therapies.